)
)
)
.png)
BIOIO is a therapeutics company developing first-in-class gerotherapies for conditions like type II diabetes. Lead program, BIOIO-1001, is a dual insulin/GLP-1 sensitizer.
Year Founded
2023
Next catalyst (value inflection) update
DC nomination for BIOIO-1001
Expected time of next catalyst update
Jul-26
City
St. Louis
Country
United States
Company CEO or top company official
Tim Peterson
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
BIOIO-1001 - a dual Insulin and GLP-1 sensitizer for type II diabetes and related co-morbidities.
Number of Unlicensed Products
2
Therapeutic Area
Metabolic Diseases
Website
https://bioio.tech
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
